Fig 2: The target relationship between SNHG1 and PARP6 in HSCC cells. (a) RNA pull-down and (b) RNA immunoprecipitation (RIP) assay to detect the binding of SNHG1 and PARP6 in FaDu cells. Data are expressed as mean ± SD (n = 3). ∗∗P < 0.01, compared with anti-IgG.

Fig 3: SNHG1/PARP6 axis affected the protein expression of XRCC6, β-catenin, and EMT-related proteins (E-cadherin and N-cadherin) in HSCC cells by western blot assay. FaDu cells were transfected with lenti-NC, lenti-PARP6, sh-NC, or/and sh-SNHG1. Data are expressed as mean ± SD (n = 3). ∗∗P < 0.01, compared with lenti-NC. ##P < 0.01, compared with sh-NC + lenti-PARP6 group.

Fig 4: The expression of PARP6, XRCC6, β-catenin, and EMT-related proteins (E-cadherin and N-cadherin) in HSCC cells by western blot assay. FaDu cells were transfected with sh-NC, sh1-SNHG1, or sh2-SNHG1. Data are expressed as mean ± SD (n = 3). ∗∗P < 0.01, compared with sh-NC.

Fig 5: Effects of SNHG1/PARP6 axis in the expression of PARP6, XRCC6, β-catenin, and EMT-related proteins (E-cadherin and N-cadherin) in HSCC in vivo. Western blotting was used to detect the expression of PARP6, XRCC6, β-catenin, E-cadherin, and N-cadherin in tumor tissues of differently treated mice. BALB/c nude mice were subcutaneously injected with FaDu cells that were transfected with lenti-NC, lenti-PARP6, sh-NC, or/and sh-SNHG1. Data are expressed as mean ± SD (n = 5). ∗∗P < 0.01, compared with the lenti-NC group. #P < 0.05 and ##P < 0.01, compared with the sh-NC + lenti-PARP6 group.